Drug Profile
BLI 801
Alternative Names: BLI801Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Braintree Laboratories
- Class Laxatives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Constipation
Most Recent Events
- 24 Sep 2021 BLI 801 is still in phase II/III trials for Constipation in USA (Sebela Pharmaceuticals pipeline, September 2021)
- 01 Apr 2017 Braintree Laboratories completes a phase II/III clinical trials in Constipation in USA (NCT02822508)
- 01 Jun 2016 Phase-II/III clinical trials in Constipation in USA (PO) (NCT02822508)